

Macarena SimÃ³n-Talero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070185/publications.pdf>

Version: 2024-02-01

29
papers

1,785
citations

471061

17
h-index

476904

29
g-index

31
all docs

31
docs citations

31
times ranked

1997
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	0.6	296
2	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281.	1.8	259
3	Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy. <i>Hepatology</i> , 2013, 57, 2448-2457.	3.6	217
4	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	0.6	162
5	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	1.8	152
6	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. <i>Journal of Hepatology</i> , 2013, 59, 1184-1192.	1.8	102
7	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	1.8	97
8	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	3.6	95
9	Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.	1.8	85
10	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 619-629.	1.4	45
11	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 718-725.	1.4	34
12	Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520.	1.5	30
13	Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096128.	1.4	30
14	Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 823-835.	1.4	25
15	Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 538-580.	0.2	20
16	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	1.9	20
17	Prognostic Assessment in Patients with Hepatic Encephalopathy. <i>Disease Markers</i> , 2011, 31, 171-179.	0.6	18
18	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 1214-1219.	0.4	15
20	Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. <i>World Journal of Gastroenterology</i> , 2015, 21, 10475.	1.4	12
21	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 3093-3102.	1.9	11
22	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774341.	1.4	9
23	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	1.4	7
24	Should prophylactic embolization of spontaneous portosystemic shunts be routinely performed during transjugular intrahepatic portosystemic shunt placement?. <i>Digestive and Liver Disease</i> , 2018, 50, 1324-1326.	0.4	6
25	Reply to: "Definition of SPSS: we need to speak the same language". <i>Journal of Hepatology</i> , 2020, 73, 464-465.	1.8	6
26	Spontaneous portosystemic shunt embolization in liver transplant recipients with recurrent hepatic encephalopathy. <i>Annals of Hepatology</i> , 2022, 27, 100687.	0.6	6
27	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4885.	1.0	5
28	Reply to: "The importance of prognostic factors in cirrhosis". <i>Journal of Hepatology</i> , 2014, 60, 1326.	1.8	4
29	Reply. <i>Gastroenterology</i> , 2018, 155, 1650-1651.	0.6	0